D. E. Shaw & Co., Inc. Sarepta Therapeutics, Inc. Put Options Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $757,099 - $1.19 Million	10,000 New	10,000 $1.11 Million
Q2 2020 Aug 14, 2020	SELL	$93.0 - $171.7 $6.52 Million - $12 Million	-70,100 Reduced 87.52%	10,000 $1.6 Million
Q1 2020 May 15, 2020	BUY	$82.38 - $131.64 $1.56 Million - $2.49 Million	18,900 Added 30.88%	80,100 $7.84 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $765,300 - $1.36 Million	-10,000 Reduced 14.04%	61,200 $7.9 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $4.09 Million - $8.82 Million	56,200 Added 374.67%	71,200 $5.36 Million
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $33,663 - $45,585	-300 Reduced 1.96%	15,000 $2.28 Million
Q1 2019 May 15, 2019	SELL	$106.67 - $151.68 $2.13 Million - $3.03 Million	-20,000 Reduced 56.66%	15,300 $1.82 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $3.3 Million - $5.04 Million	33,900 Added 2421.43%	35,300 $3.85 Million
Q3 2018 Nov 14, 2018	SELL	$115.31 - $161.51 $3.36 Million - $4.7 Million	-29,100 Reduced 95.41%	1,400 $226,000
Q3 2017 Nov 14, 2017	BUY	$35.73 - $47.15 $1.09 Million - $1.44 Million	30,500	30,500 $1.38 Million

559

85.5M

3.67M

1.75M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.5B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.